Search for Clinical Trial Results

Sponsored By

Lung Adenocarcinoma - 25 Studies Found

Status Study
Not yet recruiting Study Name: The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar
Condition: Advanced Primary Lung Adenocarcinoma
Date: 2012-03-21
Interventions: Drug: endostar Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous dr
Completed Study Name: A+C in Metastatic Lung Adenocarcinoma Cancer
Condition: Lung Adenocarcinoma Metastatic
Date: 2016-10-24
Interventions: Drug: Crizotinib, bevacizumab Eligible patients with ALK translocation or ROS1 translocation or MET ampl
Not yet recruiting Study Name: Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung Adenocarcinomas
Condition: Metastatic Lung Adenocarcinomas
Date: 2016-08-24
Interventions: Other: Non intervention. Observation Study
Completed Study Name: Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Date: 2016-09-08
Interventions: Other: biopsies The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western b
Recruiting Study Name: Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas
Condition: Stage IV Lung Adenocarcinoma
Date: 2014-04-21
Interventions:
  • Drug: Certolizumab
  • Drug: cisplatin
Completed Study Name: Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
Condition:
  • Lung Adenocarcinoma
  • Brain Metastases

Date: 2012-04-11
Interventions:
  • Drug: erlotinib 150 mg given o
Active, not recruiting Study Name: The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR
Condition: Adenocarcinoma of Lung
Date: 2015-07-07
Interventions:
  • Biological: Cytokine-Induced Killer Cells

Completed Study Name: Tepotinib Phase II Study in Lung Adenocarcinoma Harbouring MET Exon 14 (METex14) Skipping Alterations
Condition: Lung Adenocarcinoma Stage IIIB/IV
Date: 2016-07-29
Interventions: Drug: tepotinib Subjects received 500 mg of tepotinib tablet once daily orally during each 21 day cycle
Completed Study Name: Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma
Condition: Adenocarcinoma of Lung
Date: 2016-06-15
Interventions:
  • Drug: recombinant human endostatin

Completed Study Name: Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma
Condition: Adenocarcinoma of Lung (Disorder)
Date: 2016-03-30
Interventions: Genetic: Sequencing of ctDNA in plasma Sequencing of ctDNA in plasma
<<< Previous | Next >>>